| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2567069 | Pulmonary Pharmacology & Therapeutics | 2014 | 7 Pages |
Abstract
Roflumilast significantly reduces the mean exacerbation rate in COPD patients. Although there are insufficient clinical evidence on other clinical endpoints and high risk of some adverse events, roflumilast therapy may benefit COPD patients. Further studies are needed to pay more attention to the long-term efficacy and safety of roflumilast.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Jun-Hong Yan, Wan-Jie Gu, Lei Pan,